Clinical TrialTreatment-Resistant Depression (TRD)PsilocybinCompleted

The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression

This open-label, interventional trial (n=19) explored the effectiveness of 25mg of psilocybin as adjunctive therapy to SSRI use in participants with treatment-resistant depression (TRD).

Target Enrollment
19 participants
Study Type
Phase II interventional
Design
Non-randomized

Detailed Description

Open-label single-group Phase II study administering a single 25 mg dose of COMP360 psilocybin to adults with treatment-resistant depression while maintained on a single SSRI, with psychological support.

N=19 actual; rapid significant decreases in depressive symptoms were observed with over 40% of participants sustaining response at 3 months. Outcomes included HDRS-17 changes and safety/tolerability assessments.

Study Protocol

Preparation

sessions

Dosing

1 sessions

Integration

sessions

Therapeutic Protocol

support

Study Arms & Interventions

25 mg COMP360

experimental

Single-group open-label administration of 25 mg COMP360 psilocybin

Interventions

  • Psilocybin25 mg
    via Oral• single dose• 1 doses total

    COMP360 formulation; adjunctive to a single SSRI

Participants

Ages
18 – 99
Sexes
Male & Female

Inclusion Criteria

  • Inclusion Criteria:
  • 1. Signed ICF.
  • 2. 18 years of age or older
  • 3. At least moderate MDD
  • 4. Hamilton Depression Rating Scale (17 item) score ≥18
  • 5. Currently receiving treatment with a selective serotonin reuptake inhibitor
  • 6. Failure to respond to an adequate dose and duration of 2, 3, or 4 pharmacological treatments
  • 7. McLean Screening Instrument for Borderline Personality Disorder <7 at Screening (V1).
  • 8. Ability to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits.

Exclusion Criteria

  • Exclusion Criteria:
  • Psychiatric Exclusion Criteria:
  • 1. Current or past history of schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, or borderline personality disorder, as assessed by medical history, McLean Screening Instrument for Borderline Personality Disorder and a structured clinical interview (version 7.0.2 MINI).
  • 2. Prior electroconvulsive therapy and/or ketamine for current episode.
  • 3. Ongoing use of an antidepressant medication, including augmentation or combination therapies, other than a single SSRI
  • 4. Current psychological therapies that will not remain stable within 21 days of the psilocybin session. Psychological therapies cannot be initiated within 21 days of baseline.
  • 5. Current (within the last year) alcohol or substance use disorder as informed by DSM 5 (diagnosed by MINI 7.0.2) at Screening (V1).
  • 6. Significant suicide risk as defined C-SSRS within the past year
  • 7. Depression secondary to other severe medical conditions according to clinicians' judgement.
  • 8. Other personal circumstances and behaviour judged to be incompatible with establishment of rapport or safe exposure to psilocybin, including exposure to psilocybin within the past year and use of psychedelics, such as ayahuasca, during the current depressive episode.
  • General Medical Exclusion Criteria:
  • 9. Women who are pregnant, nursing or planning a pregnancy.
  • 10. Cardiovascular conditions
  • 11. Uncontrolled or insulin dependent diabetes.
  • 12. Seizure disorder.
  • 13. Positive urine drug screen for illicit drugs or drugs of abuse
  • 14. Current enrolment in any investigational drug or device study or participation in such within 30 days prior to Screening (V1).
  • 15. Current enrolment in another clinical study of an investigational medical or participation in such within 30 days of Screening (V1).
  • 16. Abnormal and clinically significant results on the physical examination, vital signs, ECG or laboratory tests at Screening (V1).
  • 17. Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study.

Study Details

Locations

Kadima Neuropsychiatry Institute — La Jolla, California, United States
Sheaf House, Tallaght Hospital — Dublin, Ireland

Your Library